TSE:4528Pharmaceuticals
Ono Pharmaceutical (TSE:4528) Files Ripretinib in Japan: Is Its Oncology Strategy Entering a New Phase?
Ono Pharmaceutical has submitted a manufacturing and marketing application in Japan for ripretinib, an oral tyrosine kinase inhibitor for advanced gastrointestinal stromal tumor that has progressed after prior chemotherapy, supported by positive global Phase 3 INVICTUS data showing significantly prolonged progression-free survival versus placebo.
The filing is reinforced by ripretinib’s orphan drug status and its designation as a high medical-need therapy in Japan, highlighting its potential...